Tarceva access trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
OSI/Genentech's new Phase IIIb Tarceva trial, announced Sept. 10, is intended to provide access to the non-small cell lung cancer therapy before approval, Genentech says. Patients will be enrolled in the open-label Access to Care, Tarceva (ACT) study up until FDA's decision, which is expected in early 2005, and may remain in the study until nine months post-approval. Survival and response rates are co-primary endpoints. Although Tarceva (erlotinib) showed a two month survival benefit in its pivotal study, the design of the trial would make it easier to collect additional survival data after commercial approval. An earlier Phase III combination study did not show a survival benefit (1Pharmaceutical Approvals Monthly Feb. 1, 2004, In Brief). Genentech plans to submit the data at the end of the study...
You may also be interested in...
Tarceva NDA gets rolling
Roche/Genentech/OSI expect to complete the rolling NDA for Tarceva (erlotinib) in mid-2004, for treatment of incurable stage IIIB/IV non-small cell lung cancer in patients who have failed standard therapy for advanced or metastatic disease. OSI announced submission of preclinical and chemistry, manufacturing & controls sections of the NDA Jan. 21. Data from a 730-patient, Phase III monotherapy study in refractory NSCLC is expected in the second quarter. Last October, the firms reported that the Phase III program examining Tarceva in combination with standard chemotherapy failed to show a survival benefit. In contrast to the combo trials, the study design for the monotherapy trial "was based on very solid Phase II data," OSI CEO Colin Goddard, PhD, said. Approval is expected at the end of 2004…
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.